Mineralys Therapeutics, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Mineralys Therapeutics, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock RADNOR, PA, June 3, 2026 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other dise…